Voyageur Pharmaceuticals Ltd (VM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Voyageur Pharmaceuticals Ltd (VM) has a cash flow conversion efficiency ratio of -0.295x as of November 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-369.98K ≈ $-267.64K USD) by net assets (CA$1.25 Million ≈ $906.00K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VM equity financing ratio to measure how much of total assets are equity-financed.
Voyageur Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Voyageur Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check VM cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Voyageur Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Voyageur Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Initiator Pharma A/S
ST:INIT
|
-0.144x |
|
AlphaVest Acquisition Corp Ordinary Shares
NASDAQ:ATMV
|
0.004x |
|
Hui Srl
VI:HUI
|
N/A |
|
ATP 30 Public Company Limited
BK:ATP30
|
0.090x |
|
Neurosense Therapeutics Ltd
NASDAQ:NRSN
|
1.177x |
|
Zhonglu Co Ltd B
SHG:900915
|
0.056x |
|
Artego Tg. Jiu
RO:ARTE
|
N/A |
|
INCREDIBLE INDUSTRIES LIMITED
NSE:INCREDIBLE
|
0.019x |
Annual Cash Flow Conversion Efficiency for Voyageur Pharmaceuticals Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Voyageur Pharmaceuticals Ltd from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Voyageur Pharmaceuticals Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-11-30 | CA$1.25 Million ≈ $906.00K |
CA$-2.89 Million ≈ $-2.09 Million |
-2.310x | -243.80% |
| 2024-11-30 | CA$449.96K ≈ $325.49K |
CA$-302.29K ≈ $-218.67K |
-0.672x | +2.69% |
| 2023-11-30 | CA$1.44 Million ≈ $1.04 Million |
CA$-991.25K ≈ $-717.06K |
-0.690x | +41.17% |
| 2022-11-30 | CA$1.46 Million ≈ $1.06 Million |
CA$-1.72 Million ≈ $-1.24 Million |
-1.174x | -35.22% |
| 2021-11-30 | CA$1.91 Million ≈ $1.38 Million |
CA$-1.65 Million ≈ $-1.20 Million |
-0.868x | +2.33% |
| 2020-11-30 | CA$306.33K ≈ $221.60K |
CA$-272.19K ≈ $-196.90K |
-0.889x | -5.05% |
| 2019-11-30 | CA$754.09K ≈ $545.50K |
CA$-637.81K ≈ $-461.38K |
-0.846x | +11.07% |
| 2018-11-30 | CA$515.68K ≈ $373.04K |
CA$-490.45K ≈ $-354.79K |
-0.951x | -113.60% |
| 2017-11-30 | CA$-89.24K ≈ $-64.55K |
CA$-624.24K ≈ $-451.56K |
6.995x | +13473.35% |
| 2016-11-30 | CA$670.46K ≈ $485.00K |
CA$-35.07K ≈ $-25.37K |
-0.052x | +94.07% |
| 2015-11-30 | CA$80.07K ≈ $57.92K |
CA$-70.65K ≈ $-51.11K |
-0.882x | -204.17% |
| 2014-11-30 | CA$81.56K ≈ $59.00K |
CA$-23.66K ≈ $-17.11K |
-0.290x | +6.71% |
| 2013-11-30 | CA$176.02K ≈ $127.33K |
CA$-54.73K ≈ $-39.59K |
-0.311x | -3070.28% |
| 2012-11-30 | CA$221.34K ≈ $160.12K |
CA$2.32K ≈ $1.68K |
0.010x | +106.87% |
| 2011-11-30 | CA$185.00K ≈ $133.83K |
CA$-28.19K ≈ $-20.39K |
-0.152x | -- |
About Voyageur Pharmaceuticals Ltd
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The co… Read more